Bio-Path Hopes To Blaze Profitable Path With Antisense Drugs
Executive Summary
Bio-Path Holdings is trying to become the next company to make it big with antisense drugs. Recently, the Houston-based biotech released data showing its lead compound, which is known as BP-1001, may hold promise in treating advanced acute myeloid leukemia, or AML.